查詢結果分析
相關文獻
- New One-Week, Low-Dose Triple Therapy for the Treatment of Duodenal Ulcer with Helicobacter Pylori Infection
- A One-Week Low-Dose New Triple Therapy for Treatment of Duodenal Ulcer with Helicobacter Pylori Infection
- 與胃食道逆流疾病相關的胸痛
- PPIs於胃腸潰瘍出血患者之使用分析
- 質子幫浦阻斷劑或乙型組織胺受體拮抗劑是否影響體重
- 在哭鬧及躁動不安的嬰兒使用質子幫浦阻斷劑是無效的:一個隨機對照試驗的系統性回顧
頁籤選單縮合
題名 | PPIs於胃腸潰瘍出血患者之使用分析=Analysis of Proton Pump Inhibitors Therapy for Peptic Bleeding Ulcers |
---|---|
作者 | 張雅嵐; 張鐳[王欝]; 莊雅如; 蔡崇弘; 李建瑩; Chang, Ya-lan; Chang, Lei-yu; Chuang, Ya-ju; Tsai, Chung-hung; Lee, Chien-ying; |
期刊 | 藥學雜誌 |
出版日期 | 20160600 |
卷期 | 32:2=127 2016.06[民105.06] |
頁次 | 頁57-62 |
分類號 | 418.244 |
語文 | chi |
關鍵詞 | 質子幫浦阻斷劑; Proton pump inhibitors; Bleeding peptic ulcer; Intermittent proton pump inhibitors; Continuous proton pump inhibitors; |
中文摘要 | 背景:美國腸胃科醫學會建議,經內視鏡檢查後判定為高風險潰瘍出血患者,應 給予高劑量連續輸注質子幫浦阻斷劑 (proton pump inhibitors, PPIs),但陸續有統合分析 文獻與學會建議有所分歧,認為不論是否為高風險潰瘍出血患者,給予非高劑量 PPIs (QD/Q12 h) 其預後不劣於高劑量連續輸注 PPIs。本研究目的在了解院內潰瘍性出血患者 PPIs 使用情形並分析其預後。 方法:回溯性研究搜集本院2013年1月至2014年12月期間,經診斷疾病碼 ICD 9為 531.4-533.9、578.9之消化性潰瘍相關疾病,且接受內視鏡止血治療後之患者,使用連續 輸注 PPIs 與間歇式 PPIs 兩組之一、住院天數、二、累計紅血球輸血量 (packed red blood cells, PRBCs)、三、死亡率進行數據統計,分析兩組之預後。 結果:2013-2014年度共收錄103人,給予連續輸注 PPIs 共77人,間歇性 PPIs 共 26人。兩組效果成效的測量指標為累計輸血量、住院天數與死亡率,其 p value 分別 為0.976,0.744,0.365,均不具統計上差異;納入患者依出血風險高低進行相關係數 (Correlation coefficient, r) 分析,其結果為無論高風險或低風險出血性潰瘍患者,以高劑 量連續輸注或非高劑量 PPIs 兩種不同方式投藥,對於住院天數、輸血量與死亡率,均 不具顯著相關性。 結論:出血性潰瘍患者經內視鏡止血治療後,給予連續輸注 PPIs 並未獲得更好的 預後,以經濟層面考量應使用間歇性 PPIs。 |
英文摘要 | Backgroud: Recommendations from American college of gastroenterology indicated that patients with high-risk bleeding ulcer based on endoscopy should be administered with high-dose continuous infusion of proton pump inhibitor (PPI). Different opinion from metaanalysis studies expressed that whether patients with high-risk bleeding ulcer, the prognosis of administered with non-high dose intermittent PPI therapy (QD / Q12 h) is not inferior to highdose continuous infusion of PPI therapy. The purpose of this study is to investigate the usage of PPI in patients with bleeding ulcer in hospital and analyze the prognosis. Method: We performed a retrospective study from 2013 to 2014 in our hospital. ICD-9- CM diagnosis codes of peptic ulcer-related diseases were 531.4 -533.9 and 578.9, endoscopic hemostasis performed in these patients after treatment. To compare the outcomes between highdose continuous infusion PPI therapy with non-high dose intermittent PPI therapy, including the hospital length of stay, transfusion of packed red blood cells (PRBCs) and mortality. To compare the prognosis in these two groups from statistical analysis. Results: This study enrolled 103 patients, 77 patients administrated with high dose continuous infusion PPI therapy, 26 patients administrated with non-high dose intermittent PPI therapy. There were no significant differences between two study groups in any of hospital length of stay, transfusion of PRBCs and mortality. (respectively, p value 0.976, 0.744, 0.365). Furthermore, we analyzed the correlation of coefficient (r) in patients divided into high and low bleeding risk. Comparison between high-dose PPI therapy with non-high dose PPI therapy, there was no significant correlation between two groups in hospital length of stay, transfusion of PRBCs and mortality. Conclusion: Patients with bleeding ulcer after endoscopic hemostasis, administrated with high dose continuous infusion PPI therapy did not get better prognosis, intermittent PPI therapy was recommended when considering with economic aspects. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。